CDKL2 and neoplasm: In this subgroup analysis, CDKL2 downregulation was associated with certain clinicopathological factors including gender, poor tumor grade, advanced TNM stages, positive nodal invasion, metastasis, tumor status, and survival of patients with ccRCC.